Ahead of Alzheimer’s stands at the forefront of a new era, one where brain health and wellness become a national priority, early detection becomes standard, and Alzheimer’s is no longer a passive diagnosis, but an active, manageable condition. Our show brings together patients, families, caregivers, clinicians, researchers, policymakers, and thought leaders to explore the science, stories, breakthroughs, and policy conversations that can help people understand risk, recognize possibility, and act sooner. In this episode, Emily Kaplan sits down with Angela Calman, founder of the Alliance to End Protein Misfolding Disease and former VP of communications at 23andMe. Angela shares her unique perspective on the intersection of healthcare, personal genetic testing, and chronic illness. After discovering she carries two copies of the ApoE4 gene, she shifted her focus to proactive lifestyle interventions to mitigate her risk. Genetic markers are only part of the story. Angela details her parallel journey navigating a sudden, life-threatening diagnosis of amyloidosis while simultaneously managing care for her parents. By contrasting her father’s late-stage diagnosis with her mother’s early-stage detection, she highlights how starkly different lifestyles and health spans impact the trajectory of cognitive decline. Watch the episode to learn about the critical value of early diagnostic testing and how reclaiming control over your health data can change your future.